[{"orgOrder":0,"company":"Lonza Group","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"VX-880","moa":"Pancreatic isleT-cell","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intraportal Infusion","sponsorNew":"Lonza Group \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Lonza Group \/ Vertex Pharmaceuticals"}]

Find Endocrinology Clinical Drug Pipeline Developments & Deals by Lonza Group

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BPI Europe
                          Not Confirmed
                          BPI Europe
                          Not Confirmed

                          Details : The collaboration aims to support the manufacture of Vertex’s portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with T1D, focusing on the VX-880 (STx-02) and VX-264 programs in clinic...

                          Product Name : VX-880

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          June 26, 2023

                          Lead Product(s) : VX-880

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Vertex Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank